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Introduction
Juvenile dermatomyositis (JDM) is a multisystem disease
of uncertain origin resulting in chronic muscle and skin
inflammation. Disease’s complications are calcinosis and
cutaneous ulcerations, lipodystrophy, joint contractures,
interstitial lung disease, cardiac involvement, digestive
and central nervous system vasculitis.
Objectives





A 16 year old girl was admitted for fever, diffuse pain,
asthenia, sore throat and generalised papular rash. Initial
work-up showed leukopenia, elevation in creatine phos-
phokinase (CK) (650 U/l) and transaminase. Epstein-Barr
Virus (EBV) serology was compatible with acute infection
and the initial treatment was symptomatic.
Subsequent deterioration of general conditions,
progressive polymyositis with regular increase in muscle
enzymes (CK up to 39000 U/l), massive muscle swelling and
maculo-papular rash were consistent with a diagnosis of
JDM. MRI confirmed muscular inflammatory involvement.
Sudden onset of blurred vision, haemolytic anaemia
(haemoglobin 53 g/l and schistocytes) and thromobocy-
topenia (21 G/l) lead to further investigation. Complete
work-up showed Purtscher-like retinopathy, renal failure
(creatinine 150 umol/l) and pancreatitis (lipase 570 U/l).
Renal and Muscle biopsy showed microangiopathy with
capillary endothelium necrosis and mild inflammation
consistent with JDM and TMA. Dosing of ADAMST-13
activity was normal.
Patient failed to respond to pulse therapy with methyl-
prednisolone, intravenous immunoglobulin, plaquenil,
rituximab and cyclophosphamide. Patient showed also
partial response to plasma exchange therapy, with suc-
cessive deterioration of clinical conditions and biological
parameters.
Treatment with Eculizumab, a monoclonal antibody
against the C5 protein fraction of complement system,
900 mg once/week for 5 weeks and then 1200 mg once




This report emphasizes that early recognition of TMA and
prompt treatment are important in children with severe
JDM associated with anaemia and thrombocytopenia.
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